Lv2
130 积分 2026-01-20 加入
Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study
1个月前
已完结
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
1个月前
已完结
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
1个月前
已完结
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
1个月前
已关闭
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
1个月前
已完结
Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors
1个月前
已完结
EP.02.10 Fumarate and Ass1 in KRAS-Mutant NSCLC: The Influence of Cetuximab in Combination With KRAS G12C Inhibitors (Sotorasib and Fulzerasib)
1个月前
已关闭
P2.02.39 Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect With Omeprazole Pretreatment in KRAS G12C NSCLC
1个月前
已关闭
Garsorasib in patients with KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
1个月前
已关闭
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
1个月前
已完结
皖公网安备34019202002308
